{
    "nct_id": "NCT01324518",
    "title": "Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-04-01",
    "description_brief": "The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.",
    "description_detailed": "The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of cognitive and behavioral symptoms in patients with Alzheimer's disease.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "A total of 132 subjects were screened and 100 were randomized to 3 treatment groups. 30 patients were excluded prior randomization due to inclusion/exclusion criteria, 2 due to personal reasons.",
            "recruitmentDetails": "This study was conducted in 4 countries (18 centres): Finland, Poland, Romania and Spain. Of these, 1 centre screened but did not randomise any subjects. Study period was 27 Apr 2011-21 Sep 2012 (first subject first visit to last subject last visit).",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Low Dose of ORM-12741",
                    "description": "ORM-12741: 60mg twice a day"
                },
                {
                    "id": "FG001",
                    "title": "High Dose of ORM-12741",
                    "description": "ORM-12741: 200mg twice a day"
                },
                {
                    "id": "FG002",
                    "title": "Placebo",
                    "description": "Placebo for ORM-12741: Placebo twice a day"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "33"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "33"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "34"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "28"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "30"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "33"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "5"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Low Dose of ORM-12741",
                    "description": "ORM-12741: 60mg twice a day"
                },
                {
                    "id": "BG001",
                    "title": "High Dose of ORM-12741",
                    "description": "ORM-12741: 200mg twice a day"
                },
                {
                    "id": "BG002",
                    "title": "Placebo",
                    "description": "Placebo for ORM-12741: Placebo twice a day"
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "33"
                        },
                        {
                            "groupId": "BG001",
                            "value": "33"
                        },
                        {
                            "groupId": "BG002",
                            "value": "34"
                        },
                        {
                            "groupId": "BG003",
                            "value": "100"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "71.8",
                                            "spread": "8.2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "71.8",
                                            "spread": "6.8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "72.3",
                                            "spread": "8.5"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "72.0",
                                            "spread": "7.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "calculatePct": false,
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "59"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "41"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With Adverse Events",
                    "description": "Adverse events from start of ORM-12741 treatment until end of study visit.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "33"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "33"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "34"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "21"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Quality of Episodic Memory",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Quality of Episodic Memory measures the capability of maintaining information in episodic memory and is assessed as the sum of sensitivity indices from 4 memory tasks on the CDR computerised battery tests. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Index score",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "100.7",
                                            "spread": "92.2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "85.0",
                                            "spread": "59.6"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "46.3",
                                            "spread": "62.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Quality of Working Memory",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Quality of Working Memory measures the capability of maintaining information in working memory and is assessed as the sum of sensitivity indices from 2 memory tasks on the CDR computerised battery tests. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Index score",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.20",
                                            "spread": "0.53"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.18",
                                            "spread": "0.47"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0.82",
                                            "spread": "0.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Quality of Memory",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Quality of Memory is a combination of outcome measures Quality of Working Memory \\& Quality of Episodic Memory. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Index score",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "216.53",
                                            "spread": "133.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "196.37",
                                            "spread": "93.72"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "117.15",
                                            "spread": "104.30"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Speed of Memory",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Speed of Memory is assessed as the sum of speed measures from 2 memory tasks and 2 recognition tasks on the CDR computerised battery tests. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "msec",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8287.8",
                                            "spread": "3898.2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8930.30",
                                            "spread": "5379.5"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "8082.2",
                                            "spread": "4064.1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Power of Attention",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Power of attention measures speed and attention and is assessed from 3 attentional tasks on the CDR computerised battery tests. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "msec",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1940.3",
                                            "spread": "533.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1978.0",
                                            "spread": "1040.4"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "2077.9",
                                            "spread": "995.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Continuity of Attention",
                    "description": "The Cognitive Drug Research (CDR) computerised battery tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning. Continuity of attention measures speed and accuracy and is calculated from 3 attentional tasks on the CDR computerised battery tests. Values are calculated by a computer and higher scores mean better outcome.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Index score",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "85.7",
                                            "spread": "11.0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "84.8",
                                            "spread": "15.3"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "79.7",
                                            "spread": "21.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "NPI Total Score",
                    "description": "The total score of Neuropsychiatric Inventory (NPI) was assessed by a caregiver interview. 10 behavioral areas were included: Delusions, Hallucinations, Agitation/Aggression, Depression/Dysphoria, Anxiety, Elation/Euphoria, Apathy/Indifference, Disinhibition, Irritability/Lability, and Aberrant Motor Behaviour. Higher scores mean worse outcome. Minimum value 0, maximum value 120.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14.7",
                                            "spread": "9.1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "13.7",
                                            "spread": "8.9"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "20.2",
                                            "spread": "19.0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Caregiver Distress Score",
                    "description": "Caregiver distress score generated by adding together the scores of individual NPI distress questions of Neuropsychiatric Inventory NPI. Higher scores mean worse outcome. Minimum value 0, maximum value 120.",
                    "populationDescription": "per protocol population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "28"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "9.2",
                                            "spread": "6.0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8.0",
                                            "spread": "4.3"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "11.0",
                                            "spread": "10.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Pharmacokinetics of ORM-12741",
                    "description": "ORM-12741 plasma trough concentrations at week 12.",
                    "populationDescription": "M-ITT population",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/ml",
                    "timeFrame": "3 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Low Dose of ORM-12741",
                            "description": "ORM-12741: 60mg twice a day"
                        },
                        {
                            "id": "OG001",
                            "title": "High Dose of ORM-12741",
                            "description": "ORM-12741: 200mg twice a day"
                        },
                        {
                            "id": "OG002",
                            "title": "Placebo",
                            "description": "Placebo for ORM-12741: Placebo twice a day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "32"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18.4",
                                            "spread": "13.9"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "61.0",
                                            "spread": "45.9"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0",
                                            "spread": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "3 months",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Low Dose of ORM-12741",
                    "description": "ORM-12741: 60mg twice a day",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 33,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 33,
                    "otherNumAffected": 8,
                    "otherNumAtRisk": 33
                },
                {
                    "id": "EG001",
                    "title": "High Dose of ORM-12741",
                    "description": "ORM-12741: 200mg twice a day",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 33,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 33,
                    "otherNumAffected": 14,
                    "otherNumAtRisk": 33
                },
                {
                    "id": "EG002",
                    "title": "Placebo",
                    "description": "Placebo for ORM-12741: Placebo twice a day",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 34,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 34,
                    "otherNumAffected": 16,
                    "otherNumAtRisk": 34
                }
            ],
            "seriousEvents": [
                {
                    "term": "Cholestasis",
                    "organSystem": "Hepatobiliary disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "notes": "Cholestatic syndrome",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 34
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 34
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 5,
                            "numAffected": 3,
                            "numAtRisk": 34
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 6,
                            "numAffected": 4,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 34
                        }
                    ]
                },
                {
                    "term": "Irritability",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 34
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 34
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 2,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 33
                        },
                        {
                            "groupId": "EG002",
                            "numEvents": 8,
                            "numAffected": 4,
                            "numAtRisk": 34
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Clinical Study Director",
                "organization": "Orion Global Clinical Operations",
                "email": "jutta.hanninen@orionpharma.com"
            }
        }
    },
    "target_category": "Cognitive enhancer",
    "drug": [
        "ORM-12741 (small-molecule selective \u03b12C\u2011adrenoceptor antagonist)"
    ],
    "placebo": [
        "Placebo (comparator in the trial)"
    ],
    "explanation_target": [
        "Reason: The trial title and purpose state the drug is tested for cognitive and behavioral symptoms in Alzheimer's disease; ORM-12741 is described in the literature as a selective antagonist of the alpha\u20112C adrenergic receptor (a small\u2011molecule neuromodulator), i.e., a symptomatic (neuromodulatory) approach rather than an anti\u2011amyloid or anti\u2011tau disease\u2011modifying therapy. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Act: Key extracted details and web search results \u2014 ORM\u201112741 is a synthetic small\u2011molecule developed by Orion (later DB105 in some sources) and acts as a selective \u03b12C\u2011adrenoceptor antagonist; it was tested in a randomized, double\u2011blind, placebo\u2011controlled Phase 2a AD trial that assessed cognitive outcomes (Cognitive Drug Research system) and neuropsychiatric outcomes (Neuropsychiatric Inventory). The Phase 2a report showed a positive effect on an episodic memory endpoint and on caregiver distress (NPI), and separate PET/receptor\u2011occupancy work confirms brain penetration and \u03b12C receptor engagement. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: Classification justification and caveats \u2014 ORM\u201112741 is not a biologic and does not target canonical AD pathology (amyloid/tau), so it does not fit 'disease\u2011targeted biologic' or 'disease\u2011targeted small molecule' (those categories imply targeting Alzheimer pathology). Because its mechanism is neuromodulatory to improve cognition/symptoms, the closest category is 'Cognitive enhancer'. Note: the trial explicitly targeted both cognitive and behavioral (neuropsychiatric) symptoms \u2014 therefore there is overlap with 'Neuropsychiatric symptom improvement'; the primary cognitive endpoints and the trial title justify choosing 'Cognitive enhancer' while acknowledging the dual symptomatic aim. Supporting sources: Phase\u20112 trial report (PMC/PubMed), PET occupancy/translational study, and drug monograph entries. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search1\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug ORM-12741 is a small\u2011molecule selective antagonist of the \u03b12C\u2011adrenoceptor (an adrenergic neurotransmitter G\u2011protein coupled receptor). The trial tested it as a symptomatic/cognitive\u2011enhancing agent for cognitive and behavioral symptoms in AD rather than as an anti\u2011amyloid or anti\u2011tau disease\u2011modifying therapy. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Act: Extracted facts and assignment \u2014 ORM\u201112741 has high affinity and selectivity for the human \u03b12C\u2011adrenoceptor, shows brain penetration and receptor occupancy in human PET studies, and produced signals on episodic memory and neuropsychiatric endpoints in a Phase 2a trial. These properties identify the molecular target as a neurotransmitter receptor (adrenergic \u03b12C), so the most specific CADRO category is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search1\ue202turn0search4\ue202turn0search3\ue201",
        "Reflect: The classification aligns with the mechanism: blocking an adrenergic receptor is a neuromodulatory approach (symptomatic/cognitive enhancement) and does not target core AD pathologies (amyloid, tau, etc.). No evidence in the cited material indicates multi\u2011target disease modification, so D) is appropriate. Key supporting sources are a translational PET occupancy study and the Phase 2a clinical trial report. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Sources:",
        "- Translational PET/receptor\u2011occupancy study showing ORM\u201112741 is a selective \u03b12C\u2011AR antagonist with human brain occupancy. \ue200cite\ue202turn0search1\ue201",
        "- Phase 2a randomized, double\u2011blind, placebo\u2011controlled AD trial reporting cognitive (episodic memory) and neuropsychiatric effects and safety data. \ue200cite\ue202turn0search4\ue201",
        "- Orion press release / company description summarizing the Phase II data and mechanism (\u03b12C antagonist). \ue200cite\ue202turn0search3\ue201"
    ]
}